AHT-102 is a novel bispecific antibody that effectively targets CLDN18.2-expressing gastric cancer cells while maintaining a favorable safety profile by minimizing excessive immune activation.

Preclinical evaluations demonstrated that AHT-102 provides significant dose-dependent tumor suppression and possesses predictable pharmacokinetic properties in animal models.

The specific tissue targeting and low risk of systemic toxicity observed in this study support the further investigation of AHT-102 as a promising therapeutic candidate for patients with CLDN18.2-positive cancers.